1/33
Looks like no tags are added yet.
Factor V Leiden disease
inherited genetic disorder (most common inherited thrombophilia)
mutation in factor V → resistance to activated Protein C → decreased activation of factor V
increased risk for DVT/PE
Antiphospholipid Syndrome (APS)
autoantibodies that promote clot formation
venous/arterial thrombosis and recurrent pregnancy loss
Acquired risk factors for DVT/PE
cancer
pregnancy/estrogen
immobility
surgery
Pathophysiology of Hypercoagulability
↑ thrombin → ↑ fibrin → pathologic clot formation
vascular obstruction → decreased perfusion → ischemia or infarction
Clinical manifestations of DVT
unilateral leg swelling
pain
warmth
redness
Clinical manifestations of PE
sudden dyspnea
chest pain
tachycardia
Managing & preventing PE/DVT
Anticoagulants
early ambulation, compression devices, hydration, smoking cessation
Nursing Priorities → monitor for thrombosis, bleeding, and treatment complications
Antithrombotic Therapy
Used to prevent or treat harmful blood clot formation
Reduces platelet aggregation, inhibits clotting factors, or dissolves fibrin clots
antiplatelets
anticoagulants
thrombolytics
Aspirin
Cox -1 inhibitor anti-platelet
irreversibly inhibits cox-1 → ↓ thromboxane A → ↓ platelet activation + aggregation
PO
major ADR: Bleeding, GI irritation/ulcers
Safety: avoid with active bleeding, Reye syndrome risk in children with viral illnesses
Clopidogrel
P2Y12 receptor inhibitor anti-platelet
blocks p2y12 receptors → ↓ platelet activation and aggregation
PO
major ADR: bleeding/hemorrhage
BLACK BOX WARNING: reduced effectiveness in CYP2C19 poor metabolizers
Nursing priorities for anti-platelet therapy
MONITOR: bleeding, bruising, black/tarry stools
INTERACTIONS: NSAIDs/anticoagulants → ↑ bleeding risk
TEACHING: do not stop prescribed therapy without provider instructions
Antiplatelets
prevent platelet aggregation → help prevent arterial clots
Eptifibatide
GP IIb/IIa inhibitor anti-platelet
blocks GP IIb/IIa receptors → prevents fibrinogen binding → ↓ platelet aggregation
IV
clinical use: ACS and other selected coronary interventions
major ADR: severe bleeding; thrombocytopenia
Nursing priorities:
monitor bleeding, platelet count, hemoglobin/hematocrit
assess IV for bleeding/hematoma
renal function may require dose adjustment
avoid unnecessary invasive procedures
report significant bleeding
Unfractionated Heparin (UPH)
Heparin
inhibits factor Xa and thrombin (IIa)
IV or SC → rapid anticoagulation
major ADR: bleeding, Heparin-induced thrombocytopenia (HIT)
monitor aPTT or anti-Xa, platelets
antidote: protamine sulfate
Low-Molecular-Weight Heparin (LMWH)
Enoxaparin
mainly inhibits Factor Xa
SC → rotate abdominal injection sites; do not rub
major ADR: bleeding; HIT less common
monitoring: platelets and renal function; no routine aPTT needed
reversal: protamine sulfate → partial reversal
Nursing Safety for Heparins
monitor bleeding
avoid IM injections
black box → spinal/epidural bleeding → possible paralysis
Heparin-Induced Thrombocytopenia (HIT)
Serious immune reaction to heparin
↑ platelet activation → ↑ blood clots (thrombosis)
key findings: > 50% drop in platelets from baseline → usually 5-10 days after starting heparin
S+S: new DVT/PE, limb pain/ischemia, skin necrosis
Nursing priorities for HIT
monitor platelet trends → > 50% decrease = suspect HIT
stop all heparin and notify provider immediately
start alternative non-heparin anticoagulant
avoid LMWH and routine platelet transfusions in acute HIT
Warfarin
Vitamin K antagonist
blocks vitamin K recycling → ↓ production of clotting factors II, VII, IX, X
PO → delayed anticoagulant effect
major ADR: bleeding/hemorrhage
black box: major or fatal bleeding
contraindications: active major bleeding; generally avoided in pregnancy
interactions: many medications and changes in vitamin K intake affect INR
Warfarin nursing priorities
Monitor PT/INR → usually 2-3
Maintain consistent vitamin K intake
antidote: vitamin K
teaching: regular INR checks; report bleeding
Direct Oral Coagulants (DOACs)
Includes Apixaban (Eliquis) and Dabigatran
monitoring: bleeding, CBC, kidney function → no INR or aPTT
interactions: NSAIDs/Aspirin ↑ bleeding risk
black box: stopping early → ↑ Thrombosis risk; spinal/epidural bleeding risk
teaching: DO NOT stop abruptly; take consistently!
Apixaban (Eliquis)
Factor Xa inhibitor → ↓ Thrombin formation
PO usually twice daily
major ADR: bleeding/hemorrhage
reversal: 4-factor PCC may be used for severe bleeding per protocol
Dabigatran
Blocks thrombin (IIa) → ↓ Fibrin formation
PO usually twice daily
major ADR: bleeding/hemorrhage
reversal: Idarucizumab → specific antidote
Nursing Considerations for all Anticoagulants
assess for bleeding → bruising, bleeding gums, hematuria, black/tarry stools
monitor for thrombosis → leg swelling/pain, sudden dyspnea, chest pain
avoid NSAIDs / aspirin
bleeding precautions → soft toothbrush, fall risks
before procedures → notify provider, maybe hold med
educate to take exactly as prescribed
immediately report uncontrolled bleeding or signs of DVT/PE
Alteplase
Fibrinolytic
converts plasminogen → plasmin → breaks down fibrin → dissolves existing clots
IV
acute ischemic stroke, PE, MI
major ADR: severe bleeding, intracranial hemorrhage
contraindications: active bleeding, intracranial hemorrhage, other bleeding risks
Von Willebrand Disease (vWD)
Inherited deficiency or dysfunction of von Willebrand factor
impaired platelet adhesion!
signs: easy bruising, nose bleeds, heavy menses, ↑ bleeding after surgery/injury
trtmt: depends on type/severity → desmopressin, vWF concentrate, antifibrinolytics
Clotting factor deficiencies
Hemophilia A → factor VIII
Hemophilia B → factor IX
X-linked bleeding disorders affecting intrinsic pathway
prolonged bleeding/easy bruising
hemarthrosis → joint pain ad swelling
factor replacement
Immune Thrombocytopenia (ITP)
Acquired autoimmune destruction of platelets
CBC shows low platelets
petechiae, purpura, mucosal bleeding, nose bleeds, gum bleeding
Disseminated Intravascular Coagulation (DIC)
Widespread clotting consumes platelets and clotting factors, resulting in bleeding
too much clotting = bleeding
bleeding, bruising, thrombosis, organ ischemia, shock
treat underlying cause, and then supportive care like platelets
Hemostatic Therapy
Used to prevent or control excessive bleeding caused by impaired clot breakdown
Promotes hemostasis through 2 major actions
↑ clotting factor availability → more clots made
↓ fibrinolysis → less clot breakdown
Can cause thromboembolic complications in susceptible patients
Desmopressin (DDAVP)
Synthetic ADH analog → hemostatic agent
stimulates V2 receptors → release of vWF and factor VIII → clot formation
IV, SC, intranasal
mild hemophilia A or von Willebrand Disease
ADR: hyponatremia, water intoxication, headache, flushing
contraindications: hyponatremia, renal impairment, some cardiac conditions
Desmopressin nursing considerations
Monitor serum sodium, fluids balance, urine output
Fluid restriction
assess headache, confusion, weight gain → hyponatremia
monitor response to therapy, repeated dose may ↓ effect over time
Transexamic Acid (TXA)
Blocks plasminogen binding to fibrin → ↓ Fibrin breakdown
PO, IV, topical
trauma, surgery, postpartum hemorrhage, heavy menses, epistaxis
seizures (high dose), hypotension (rapid IV), thrombotic complications
Aminocaproic Acid
Inhibits plasminogen activation → ↓ Plasmin → ↓ Fibrin breakdown
PO/IV
surgical bleeding, excessive fibrinolysis, hemophilia-related bleeding
hypotension (rapid IV), myopathy, thrombotic complications